MRVI Stock Analysis: Maravai Lifesciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.674m USD | 12M Return: 260% | US56600D1072 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.5M
Qual. Beats: 0
Rev. Trend: -89.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Maravai LifeSciences Holdings (MRVI) is a U.S.-based life sciences company that supplies critical inputs and analytical tools used by biopharmaceutical developers, diagnostics manufacturers, and academic research institutions. It operates two segments: TRILINK, which manufactures nucleic acid products (DNA, RNA, mRNA, and oligonucleotides) along with CleanCap capping technology and custom enzymes, and CYGNUS, which provides antibody-based analytical products and ELISA kits for detecting impurities in biologic manufacturing. Founded in 2014 and headquartered in San Diego, California, the company went public in November 2020 and operates globally across North America, Europe, the Middle East, Africa, Asia Pacific, and Latin and Central America. As a constituent of the Health Care sectors Life Sciences Tools & Services sub-industry, Maravai sits within the pick-and-shovel supplier ecosystem, providing enabling technologies and consumables rather than developing its own therapeutics.
- CleanCap mRNA demand drops as COVID vaccine orders fade
- Biotech funding crunch pressures TRILINK nucleic acid sales
- CYGNUS bioprocess analytics offsets TRILINK volume decline
| Net Income: -77.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.06 > 0.02 and ΔFCF/TA -0.83 > 1.0 |
| NWC/Revenue: 56.15% < 20% (prev 134.4%; Δ -78.23% < -1%) |
| CFO/TA -0.04 > 3% & CFO -25.3m > Net Income -77.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (148.0m) vs 12m ago 2.61% < -2% |
| Gross Margin: 34.61% > 18% (prev 29.11%; Δ 5.50% > 0.5%) |
| Asset Turnover: 27.82% > 50% (prev 24.06%; Δ 3.76% > 0%) |
| Interest Coverage Ratio: -4.70 > 6 (EBIT TTM -112.5m / Interest Expense TTM 24.0m) |
| A: 0.19 (Total Current Assets 155.7m - Total Current Liabilities 38.4m) / Total Assets 603.7m |
| B: -0.01 (Retained Earnings -6.03m / Total Assets 603.7m) |
| C: -0.15 (EBIT TTM -112.5m / Avg Total Assets 750.4m) |
| D: 0.82 (Book Value of Equity 204.6m / Total Liabilities 248.2m) |
| Altman-Z'' = 1.10 = BB |
| DSRI: 1.15 (Receivables 31.1m/27.9m, Revenue 208.8m/215.9m) |
| GMI: 0.84 (GM 29.11% / 34.61%) |
| AQI: 1.21 (AQ_t 0.51 / AQ_t-1 0.42) |
| SGI: 0.97 (Revenue 208.8m / 215.9m) |
| TATA: -0.09 (NI -77.4m - CFO -25.3m) / TA 603.7m) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of August 24, 2026, the stock is trading at USD 8.64 with a total of 9,327,552 shares traded. Over the past week, the price has changed by +51.58%, over one month by +22.55%, over three months by +97.26% and over the past year by +260.00%.
Current recommended Stop Loss: 8.00 (which is 7.4% or 1.3 ATR below the current price).
Maravai Lifesciences has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy MRVI.
- StrongBuy: 5
- Buy: 1
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 7.3 | -15.5% |
P/E Forward = 370.3704
P/S = 12.808
P/B = 4.1794
Revenue TTM = 208.8m USD
EBIT TTM = -112.5m USD
EBITDA TTM = -57.2m USD
Long Term Debt = 146.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.12m USD (from shortTermDebt, last quarter)
Debt = 206.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 29.6m
Net Debt = 136.2m USD (calculated: Debt 206.3m - CCE 70.1m)
Enterprise Value = 2.81b USD (2.67b + Debt 206.3m - CCE 70.1m)
Interest Coverage Ratio = -4.70 (Ebit TTM -112.5m / Interest Expense TTM 24.0m)
EV/FCF = -80.04x (Enterprise Value 2.81b / FCF TTM -35.1m)
FCF Yield = -1.25% (FCF TTM -35.1m / Enterprise Value 2.81b)
FCF Margin = -16.82% (FCF TTM -35.1m / Revenue TTM 208.8m)
Net Margin = -37.07% (Net Income TTM -77.4m / Revenue TTM 208.8m)
Gross Margin = 34.61% ((Revenue TTM 208.8m - Cost of Revenue TTM 136.5m) / Revenue TTM)
Gross Margin QoQ = 40.14% (prev 51.19%)
Tobins Q-Ratio = 4.65 (Enterprise Value 2.81b / Total Assets 603.7m)
Interest Expense / Debt = 11.61% (Interest Expense 24.0m / Debt 206.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -88.9m (EBIT -112.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.05 (Total Current Assets 155.7m / Total Current Liabilities 38.4m)
Debt / Equity = 1.01 (Debt 206.3m / totalStockholderEquity, last quarter 204.6m)
Debt / EBITDA = -2.38 (negative EBITDA) (Net Debt 136.2m / EBITDA -57.2m)
Debt / FCF = -3.88 (negative FCF - burning cash) (Net Debt 136.2m / FCF TTM -35.1m)
Total Stockholder Equity = 218.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.31% (Net Income -77.4m / Total Assets 603.7m)
RoE = -35.42% (Net Income TTM -77.4m / Total Stockholder Equity 218.5m)
RoCE = -30.87% (EBIT -112.5m / Capital Employed (Equity 218.5m + L.T.Debt 146.0m))
RoIC = -15.99% (negative operating profit) (NOPAT -88.9m / Invested Capital 556.0m)
WACC = 11.82% (E(2.67b)/V(2.88b) * Re(12.02%) + D(206.3m)/V(2.88b) * Rd(11.61%) * (1-Tc(0.21)))
Discount Rate = 12.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.06 | Cagr: 5.10%
[DCF] Fair Price = unknown (Cash Flow -35.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -89.41 | Revenue CAGR: -20.24% | SUE: 0.35 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.09 | Chg30d=-95.05% | Revisions=+25% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.18 | Chg30d=-59.30% | Revisions=+25% | GrowthEPS=+37.7% | GrowthRev=+13.9%
EPS next Year (2027-12-31): EPS=-0.10 | Chg30d=-9.49% | Revisions=-25% | GrowthEPS=+44.5% | GrowthRev=+6.7%
[Analyst] Revisions Ratio: +17% (up=2, down=1)